Matter Neuroscience Pitch Deck: All 17 Slides + Teardown

Matter Neuroscience’s 17-slide deck is a masterclass in narrative-driven biotech fundraising. Rather than leading with complex molecular biology, the deck establishes a high-stakes philosophical and medical problem: the global crisis of unhappiness. The company positions happiness not as a vague emotion, but as a manageable biological equilibrium defined by six neurotransmitters. By claiming a proprietary method to measure these biomarkers indirectly, Matter bridges the gap between a consumer wellness app and a clinical biotech firm. The deck successfully secured $26 million in Series A fundi…

Key takeaways

• The deck claims that feeling happy adds 10-15 healthy years to a person's life (Slide 4).
• Matter categorizes negative societal outcomes like war, criminality, and addiction as results of 'overcompensation' for unhappiness (Slide 3).
• The scientific thesis rests on happiness being defined by six specific neurotransmitters underlying human reward systems (Slide 9).
• The company admits that ideal biomarkers for happiness cannot be measured directly, necessitating their indirect measurement solution (Slide 10).
• The 'Matter Protocol' is described as an algorithm that learns from memory information to provide real-time recommendations (Slide 13).
• The product roadmap spans from consumer wearables and in-game currency to FDA-approved drug discovery (Slide 15).
• The deck omits a traditional team slide, though the intro identifies Dr. Axel Bouchon as Co-founder and CEO (Slide 1).
• There is no explicit 'Ask' slide detailing how the $26M will be allocated or what specific milestones it will fund.

Frequently asked questions

What is the core scientific claim of Matter Neuroscience?

Matter Neuroscience claims that happiness is a biological state governed by six neurotransmitters within the brain's reward system. On Slide 9, they state that while these biomarkers cannot be measured directly (Slide 10), they have developed a proprietary 'Matter Protocol' algorithm that uses memory information to measure and manage this equilibrium indirectly (Slide 13).

How does the company plan to monetize its technology?

Slide 15 outlines a broad 'option space' for monetization. This includes a consumer-facing 'happiness network' featuring direct-to-consumer health claims, in-game purchases, and events. Long-term, they aim for a 'personalized medicine' model involving digital diagnostics, generic drug repurposing, and Rx NCE (New Chemical Entity) drug discovery supported by healthcare providers and reimbursement.

What problem is Matter Neuroscience trying to solve?

The deck frames unhappiness as the 'underlying cause for all mental and social diseases' (Slide 5). Slide 3 provides a map linking unhappiness to specific global issues, including 260 million cases of depression, 1.1 billion people impacted by criminality, and 426 million people impacted by war, positioning their solution as a preventative measure for these societal ills.

Is there a product currently available to the public?

Yes, Slide 14 states that a 'Matter public beta app' is currently available for users. The company uses this beta phase to continue their clinical studies while providing the algorithm's recommendations to early adopters to help them manage their 'happiness equilibrium' through conscious reflection.

Who is leading Matter Neuroscience?

The intro slide identifies Dr. Axel Bouchon as the Co-founder and CEO. While the provided 17-slide deck summary does not include a dedicated team slide with bios for the rest of the leadership or scientific advisory board, the presence of a PhD-led founding team is central to their biotech positioning.

Matter Neuroscience pitch deck: the facts

Company

Matter Neuroscience

Year

2024

Stage

Series A

Slides

17

Sector

Biotech, Consumer app

Deck type

Investment proposal

Outcome

$26M raised

Headquarters

North America (New York, NY)

Matter Neuroscience pitch deck PDF

The full Matter Neuroscience deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Matter Neuroscience pitch deck was used for

This deck is Matter Neuroscience’s 2024 venture fundraising presentation for a roughly $26 million round focused on building a consumer biotech platform around the “science of happiness.”[1][2] It was used when the company emerged from stealth and raised institutional funding led and co-led by ARCH Venture Partners, Polaris Partners, Exor Ventures and others.[1][2][3][9][11][12][14][15] The company’s thesis, reflected in the deck and coverage, is that unhappiness is a root cause of many mental and societal illnesses and can be quantified and managed via a proprietary neuroscience-based algorithm.[1][2] The capital is primarily earmarked for continued research and development of its happiness measurement and intervention platform.[2][12]

Business model: Biotech and neuroscience company developing a consumer app and platform to measure and modulate the biology of happiness, using brain imaging and molecular-level research to generate personalized insights into users’ reward systems and emotional states.[2][6][11]

Raised

$26 million[1][2][3][4][5][8][9][11][12][13][15]

Investors

ARCH Venture Partners, Polaris Partners, Exor Ventures, Collaborative Fund[1][2][3][8][9][11][12][14][15]

Founded

2019[5][7]

Founders

Axel Bouchon, Ben Goldhirsh, Chris Shiflett[7]

Headquarters

New York City, New York, USA[12]

Industry

Biotechnology / Neuroscience-driven consumer wellness and mental health[2][6][11]

Round: Round is variously described as Series A or Seed by different credible sources; the company and some press characterize it as an initial seed round followed by a more recent round within the same $26 million package.[2][3][4][9][11][13][15]

Year: 2024[1][2][3][4][5][8][9][11][12][13][15]

Lead investor: ARCH Venture Partners, Polaris Partners, and Exor Ventures co-led the later component of the $26 million round; Polaris Partners led the initial seed component.[1][2][11][12]

Total funding: $26 million in venture funding as of February 2024.[1][2][3][4][5][8][9][11][12][13][15]

Use of funds as presented: Funding is earmarked primarily for continued research into the molecular and neural drivers of happiness and unhappiness, for advancing partnerships with academic institutions, and for building and scaling the consumer app and platform that operationalizes these findings.[2][6][11][12][14]

What happened after the Matter Neuroscience deck

As of the 2024 fundraising covered by press and databases, Matter Neuroscience successfully raised $26 million from a prominent venture syndicate and transitioned from stealth into public launch, focusing the capital on ongoing neuroscience research and development of its consumer happiness platform.[1][2][3][8][11][12]

• Company emerged from stealth with public disclosure of its $26 million round and pitch deck in February 2024.[1][2][8][1
• Established investor syndicate including ARCH Venture Partners, Polaris Partners, Exor Ventures, and Collaborative Fund.
• Advanced research collaborations and publications on brain patterns underlying positive emotions, forming the scientific

What the Matter Neuroscience deck got right

• Highly differentiated mission focused on the biology of happiness and unhappiness. Matter Neuroscience presents a distinctive and ambitious mission centered on understanding and curing or preventing unhappiness through the biology of happiness, which clearly differentiates it within biotech and mental health and is repeatedly highlighted across coverage of the deck and funding announcement.[1][2][5][8][11]
• Strong backing from reputable venture investors. The company secured $26 million from a syndicate including well-known firms such as ARCH Venture Partners, Polaris Partners, Exor Ventures, and Collaborative Fund, demonstrating strong investor confidence in both the science and the team at an early stage.[1][2][3][8][9][11][12][14][15]
• Complementary founding team with scientific and entrepreneurial experience. The founding team combines deep scientific expertise in biochemistry and neuroscience (Axel Bouchon) with entrepreneurial and business experience (Ben Goldhirsh and Chris Shiflett), which is an important factor for executing a translational biotech-to-consumer strategy.[7]
• Scientific foundation supported by academic research and publications. Matter Neuroscience grounds its product vision in academic collaborations and published work on brain patterns underlying positive emotions in the orbitofrontal cortex, lending credibility to claims about proprietary algorithms and mechanistic insight.[2][6][8]
• Effective use of stealth emergence and media coverage to amplify the deck’s impact. Emerging from stealth with a sizeable raise and a public pitch deck covered by major outlets like Business Insider provides immediate visibility and narrative clarity around the company’s thesis, investors, and use of funds.[1][2][8][11]

What could have been stronger

• Limited visibility on near-term commercialization and clinical validation. External coverage emphasizes the bold thesis that unhappiness is the root cause of nearly all societal and mental illness, but neither the article nor associated public materials provide clear, quantified clinical endpoints, regulatory strategy, or near-term commercialization roadmap in the deck’s context, leaving an investor with limited visibility on how scientific insights convert into revenue and defensible product milestones.[1][2][6][11]
• Inconsistent characterization of round stage and structure. Data providers and press disagree on whether the $26 million round should be characterized as Seed or Series A, and whether it is one round or a seed plus Series A package, which may signal that the company’s financing history and stage positioning are not communicated crisply in the deck or announcements.[2][3][4][9][11][13][15]
• Scarce evidence of user or commercial traction in deck-era materials. Public descriptions focus extensively on mission and high-level science but offer little independently verifiable information on traction metrics such as user numbers, engagement, revenue, or partnerships beyond research collaborations, suggesting the deck may underemphasize operational execution relative to scientific narrative.[2][6][8][11]

How an investor would read this deck

What draws attention

• Mission-driven framing around curing or preventing unhappiness using neuroscience and molecular biology, which is distinctive and may resonate with impact-oriented and frontier biotech investors.[1][2][5][8][11]
• Institutional support from well-known venture firms (ARCH Venture Partners, Polaris Partners, Exor Ventures, Collaborative Fund), indicating strong early validation of the team and scientific thesis.[1][2][3][8][9][11][12][14][15]
• Founding team anchored by biochemist and neuroscientist Axel Bouchon with cofounders Ben Goldhirsh and Chris Shiflett, combining scientific and entrepreneurial experience.[7]
• Use of academic research collaborations and published work (e.g., studies on distributed brain patterns underlying positive emotions) to support the scientific foundation of the platform.[2][6][8]

Risks that stand out

• Scientific and translational risk that complex constructs like happiness and unhappiness may not map neatly onto actionable biomarkers or algorithms that produce reliable, reproducible outcomes in real-world consumer settings.[2][6][11]
• Commercial risk that consumers may not adopt or consistently use a happiness-focused biotech app at scale, particularly if the product requires complex data collection or provides benefits that are hard to quantify.[2][6][8][11]
• Positioning and messaging risk from the ambitious claim to "cure unhappiness," which could attract scrutiny from regulators, clinicians, and media if not supported by rigorous evidence and careful communication.[1][2][11][12]
• Financing and staging risk stemming from inconsistent external characterization of the round as Seed vs. Series A, which may complicate expectations around maturity, valuation, and subsequent fundraising.[2][3][4][9][13][15]

Questions this deck invites

• How is Matter Neuroscience defining and measuring primary outcomes for "curing" or preventing unhappiness, and what clinical or behavioral endpoints are being pursued in ongoing and planned studies?[2][6][11]
• What is the detailed breakdown of the $26 million round structure (seed vs. Series A), and how does that map to milestones, runway, and expectations from each investor syndicate?[1][2][3][11][12][15]
• What regulatory pathways, if any, is the company targeting (e.g., wellness app vs. regulated diagnostic or therapeutic), and how does that influence product design and evidence requirements?[2][6][11]
• What traction metrics exist for the consumer platform (users, retention, engagement, preliminary revenue), and how are those incorporated into future growth projections and unit economics?[2][6][8][11]
• How proprietary and defensible are the algorithms and datasets derived from the company’s neuroimaging and molecular research, and what is the IP strategy around them?[2][6][8]

What founders can take from the Matter Neuroscience deck

• A clearly articulated, provocative thesis (such as unhappiness being a root cause of many societal and mental illnesses) can differentiate a biotech pitch and attract media and investor attention when anchored in a coherent scientific narrative.[1][2][11]
• Pairing a frontier-science mission with recognizable institutional investors and explicit co-lead roles helps signal credibility and momentum to other potential backers and partners.[1][2][3][11][12][14][15]
• Emerging from stealth with a sizeable, well-syndicated round and a public pitch deck can be an effective strategy to simultaneously raise capital and build brand awareness around a new scientific category.[1][2][8][11]
• Integrating academic collaborations and published studies into the fundraising story provides a stronger foundation for claims about novel algorithms and mechanistic insights, especially in mental health and wellbeing.[2][6][8][11]
• Ambitious language around curing or preventing complex conditions should be balanced with transparent discussion of evidence, limitations, and regulatory context to avoid confusion or skepticism among sophisticated investors.[1][2][11][12]

Matter Neuroscience pitch deck: common questions

What does Matter Neuroscience do?

Matter Neuroscience is a biotech and neuroscience startup that studies the biology of happiness and unhappiness at a molecular and brain-circuit level, then translates those findings into a consumer app and platform that can measure and modulate a person’s “biological reward system.”[2][6][11]

How much did Matter Neuroscience raise and in which round?

Matter Neuroscience raised a total of $26 million in venture funding announced around late February 2024.[1][2][3][4][5][8][9][11][12][13][15] Coverage and data providers describe this as a single institutional round, labeled either Series A or Seed depending on the source, but the company and press emphasize that the $26 million comprises an initial seed round led by Polaris Partners and a more recent round co-led by ARCH Venture Partners, Polaris Partners, and Exor Ventures.[1][2][3][11][12]

Who invested in Matter Neuroscience’s 2024 funding round?

Investors reported in credible press releases and databases for the $26 million round include ARCH Venture Partners, Polaris Partners, Exor Ventures, and Collaborative Fund, with Polaris leading the initial seed component and ARCH, Polaris, and Exor co-leading the later component.[1][2][3][8][11][12][14][15] Some secondary databases also list additional investors such as Avalon Ventures, Broadview Ventures, and Versant Ventures, but these are not consistently corroborated across primary funding announcements.[4][13][15]

What is the funding being used for?

Public reporting indicates that most of the $26 million cash infusion is allocated to continued research in neuroscience and molecular biology of happiness and unhappiness, including partnerships with academic centers, and to building out the consumer-facing platform and app that operationalizes those findings.[2][6][11][12][14]

How does Matter Neuroscience’s product work at a high level?

According to the company and press, Matter Neuroscience grounds its app and platform in neuroimaging and molecular research on positive emotions and reward circuits, using proprietary algorithms derived from studies with academic partners to quantify happiness-related brain patterns and generate personalized recommendations or insights for users.[2][6][8][11]

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• Matter Neuroscience Secures $26M in Funding to Cure Unhappiness
• Here's the Pitch Deck Matter Neuroscience Used to Raise $26 Million
• Matter Neuroscience Stock Price, Funding, Valuation ... - CB Insights
• Matter Neuroscience: Funding, Team & Investors | Startup Intros
• Startup de biotecnologia arrecada US$ 26 milhões com promessa de prevenir a infelicidade
• Science | Matter App
• About - Matter Neuroscience
• News - Matter Neuroscience

Related fundraising guides (24)

• Cube Pitch Deck Teardown: A $30M Series B Masterclass in Narrative Simplicity
• authID.ai Pitch Deck Teardown: A Post-IPO Roadmap for Biometric Identity Verification
• Yalo Pitch Deck Teardown: Dominating Enterprise Conversational AI via WhatsApp
• Haystack Oncology Pitch Deck Teardown: A Masterclass in Pedigree-Driven Biotech Fundraising
• Cowboy Pitch Deck Teardown: A Masterclass in High-End Lifestyle Branding and Urban Mobility
• Arist Pitch Deck Teardown: The $12M Series A Memo Strategy for Micro-Learning
• Trash Warrior Pitch Deck Teardown: Disrupting the $56B Commercial Waste Collection Market
• Groundcover Pitch Deck Teardown: Leveraging eBPF to Disrupt Cloud Observability Costs
• CMR Surgical Pitch Deck Teardown: A $600M Masterclass in Ecosystem-Led Medical Robotics
• Altana Pitch Deck Teardown: Mapping the Global Supply Chain with Federated Learning
• Heali Pitch Deck Teardown: Leveraging Clinical Validation to Secure a $3M Seed Round
• FX HedgePool Pitch Deck Teardown: Disintermediating the $66 Trillion FX Swap Market
• Checkstep Pitch Deck Teardown: A 7-Slide Product Showcase for AI Content Moderation
• Friday Finance Pitch Deck Teardown: A $20M Series A Built on Aggregation and Social Proof
• Layla Pitch Deck Teardown: A $3M Seed Round Built on AI-Powered Travel Discovery
• Examedi Pitch Deck Teardown: A Lean Vision for Latin American Healthcare Logistics
• Chptr Pitch Deck Teardown: Modernizing the $120B Death Industry for Digital Natives
• Affini-T Therapeutics Pitch Deck Teardown: A $175M Masterclass in Biotech Platform Credibility
• IRLY Pitch Deck Teardown: A Gen-Z Dating Playbook Built on Video-First Interaction
• Equinom Pitch Deck Teardown: Solving the 250% Plant-Based Cost Gap Through Seed Genetics
• Bringg Pitch Deck Teardown: A Masterclass in Enterprise SaaS Traction and Scale
• Hedra Pitch Deck Teardown: A $32M Series A Built on Capital-Efficient AI Research
• HTEC Group Pitch Deck Teardown: Scaling Global Engineering Services via M&A and Talent Density
• Eliyan Pitch Deck Teardown: Solving the Chiplet Interconnect Bottleneck for AI

Decks from the same year (1)

• 2024 pitch deck examples

Decks from the same region (1)

• US pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $10M to $50M

Browse companies alphabetically (1)

• Pitch decks from companies starting with M

More pitch deck teardowns (16)

• Matchory Pitch Deck Teardown: Automating Global Procurement with Real-Time Data
• Materials Nexus Pitch Deck Teardown: Accelerating Material Discovery with Quantum AI
• Mathison Pitch Deck Breakdown: Scaling an End-to-End DEI Platform with $7.1M ARR
• MA THOR Solar Light Pitch Deck Teardown: A $5M Ask for Hybrid-Propulsion UAVs
• Matia Pitch Deck Teardown: Consolidating the Fragmented DataOps Stack
• Mattermark 1st Series A Deck Teardown: A Data-Heavy Masterclass in Early SaaS Traction
• Mattermark Series A Pitch Deck Teardown: Selling Data Intelligence to the Data-Hungry
• Mattermark Pitch Deck Breakdown: Selling the 'Google for Business People' Vision
• Matterport Pitch Deck Breakdown: A Masterclass in SPAC Financial Modeling and Market Dominance
• Maturious Pitch Deck Teardown: Solving Age Bias with 360-Degree Capability Profiling
• MAUI Imaging Pitch Deck Teardown: A Deep Dive into $14M Series D Ultrasound Innovation
• Maxnui Foodventures Pitch Deck Teardown: A Subscription Model for Indian Urban Nutrition
• MayaMD Pitch Deck Breakdown: A Clinical AI Deck With No Team, No Ask, And Patient Data On Slide 17
• Maybe Pitch Deck Breakdown: Modernizing Financial Planning & Wealth Management
• Maza Pitch Deck Teardown: Solving Financial Identity for the Non-SSN Market
• MBE Academy Pitch Deck Teardown: Scaling Vocational Training in Nigeria

Recently published pitch deck teardowns (12)

• Amplify Pitch Deck Teardown: A $20M Series B Masterclass in Market Re-Education
• Angle Health Pitch Deck Teardown: A $58M Series A Masterclass in Full-Stack Disruption
• Candidate.fyi Pitch Deck Teardown: A $1.3M Seed Round Built on the Candidate Experience Gap
• Cerca Pitch Deck Teardown: Leveraging Mutual Connections to Solve Dating App Fatigue
• Centuro Global Pitch Deck Teardown: A Product-First Approach to Global Compliance
• Circ Pitch Deck Teardown: Solving the Polycotton Recycling Gap with Hydrothermal Tech
• Clyx Pitch Deck Teardown: Solving the Loneliness Epidemic with High-Retention IRL Socializing
• Climatiq Pitch Deck Teardown: The Infrastructure Play for Enterprise Carbon Intelligence
• CMR Surgical Pitch Deck Teardown: A $600M Masterclass in Ecosystem-Led Medical Robotics
• ComBio Pitch Deck Teardown: A $90M Growth Round Built on Industrial Decarbonization
• Craft.io Pitch Deck Teardown: A $8M Series A Masterclass in Product-Led Narrative
• Covey Pitch Deck Teardown: Decentralizing Asset Management via Immutable Track Records

Fundraising library · Pitch deck examples · Investor directory · Founder database